FluTrends and DPT Labs team up to manufacture product under GMP
Reston, VA, July 20, 2011 — FluTrends and DPT Labs are partnering to manufacture an initial trial production batch of their upcoming naturally-derived product beginning in the fall of 2011.
Working together under a technology transfer agreement, FluTrends and DPT Labs will be employing the principles of good manufacturing practice (GMP) to ensure product quality. They will produce an initial batch of the new product in order to begin the testing phase.
DPT’s large manufacturing facilities will allow them to scale manufacturing to the highest degree possible in times of great need, making them an ideal partner in pandemic preparedness. “We are pleased to be working with such a large and reputable manufacturer,” says Dr. Steven Schwartz, FluTrends Founder and Chief Medical Officer.
The new product is a convenient nasal and throat spray that provides contains elderberry extract, a blend of herbs and essential oils, as well as other natural ingredients.
DPT is a contract development and manufacturing organization (CDMO) providing companies the best solutions to their sterile, semi-solid and liquid pharmaceutical development and manufacturing needs through innovation, technology, and service. Specializing in semi-solid and liquid dosage forms, DPT has a reputation for quality, unmatched technical expertise, extensive manufacturing capabilities, and an exemplary regulatory compliance record. DPT offers full service outsourcing solutions including pharmaceutical development, state-of-the-art manufacturing, packaging, and worldwide distribution.
FluTrends was founded in 2009 to fulfill its mission of saving lives, reducing morbidity and lessening the economic impact of influenza with the intent to eliminate it in the next decade. It is dedicated to the development and commercialization of flu-prevention products through a multi-layered program using research, biotechnology and personal protection. The long-term goal is to prevent potential pandemics and ultimately eradicate influenza with a definitive cure. Company headquarters are located in Reston, VA with research facilities in Denver, CO.
Contact:
Christopher Nelson, CFO
FluTrends International Corporation
11710 Plaza America Drive, Suite 950
Reston, Virginia 20190
P: (303) 974-7510
www.flutrends.com